Biotechnology - Licensing

Filter

Current filters:

Licensing

Popular Filters

1 to 25 of 391 results

Astellas and CoMentis to end Alzheimer’s collaboration

20-10-2014

Japanese drug major Astellas Pharma and US biotech firm CoMentis have said they will end their worldwide…

Astellas PharmaBiotechnologyCoMentisLicensingNeurologicalResearch

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

Aduro expands deal with Janssen to lung cancer; worth up to $817 million

17-10-2014

Privately-held US cancer immunotherapy developer Aduro BioTech has entered into its second agreement…

Aduro BioTechBiotechnologyGlobalJanssen BiotechJohnson & JohnsonLicensingOncologyResearch

Auspherix and Domainex collaborate for new drugs to combat antibiotic-resistance

Auspherix and Domainex collaborate for new drugs to combat antibiotic-resistance

15-10-2014

UK biotech firm Domainex and Australian drug discovery company Auspherix, a spin-out from the University…

AuspherixAuspherix PtyAustraliaBiotechnologyDomainexHealthLicensingPharmaceutical sciencesPharmacologyResearchUK

Imaxio signs option for a license agreement with DKFZ

14-10-2014

French vaccine focussed biotech firm Imaxio has signed an option for a license agreement with the German…

Anti-viralsBiotechnologyImaxioLicensingResearch

After nine years, AstraZeneca finally ditches Targacept

12-10-2014

On October 8, 2014, Anglo-Swedish pharma major AstraZeneca finally terminated its collaborative research…

AstraZenecaBiotechnologyGenito-urinaryLicensingNeurologicalTargacept

Roche acquires exclusive rights to AbVitro's extension-based target enrichment technology

Roche acquires exclusive rights to AbVitro's extension-based target enrichment technology

09-10-2014

Swiss drug major Roche has acquired exclusive rights to a primer extension-based target enrichment technology…

AbVitroBiotechnologyLicensingRocheSwitzerland

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

MedImmune and Shionogi sign license agreement for Shionogi's preclinical biologics in acute coronary syndrome

09-10-2014

MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca,…

BiotechnologyCardio-vascularCrestorJapanLicensingMedImmuneShionogi

UK Bioscience Forum: Incentivize investors to hold their investment for more than 10 years

UK Bioscience Forum: Incentivize investors to hold their investment for more than 10 years

08-10-2014

One of the main messages from the keynote speech at the UK Bioscience Forum by Paul Drayson, chief executive…

BiotechnologyLegalLicensingPatents & Trade marksProductionRegulationResearchSocial IssuesUK

New Coronado Biosciences unit to acquire and license dermatology products for commercialization

New Coronado Biosciences unit to acquire and license dermatology products for commercialization

08-10-2014

US biopharma company Coronado Biosciences has formed a wholly-owned subsidiary, Journey Medical Corporation…

BiotechnologyCoronado BiosciencesDermatologicalsJourney Medical CorpLicensingManagementUSA

Merck Serono links with ICR and Wellcome Trust on anti-cancer drugs

Merck Serono links with ICR and Wellcome Trust on anti-cancer drugs

07-10-2014

German life sciences major Merck KGaA says its biopharma division Merck Serono has entered into a co-development…

BiotechnologyGermanyLicensingMerck KGaAMerck SeronoOncologyResearch

CleveXel Pharma licenses two new oncology patents from SATT Sud Est

CleveXel Pharma licenses two new oncology patents from SATT Sud Est

06-10-2014

French company CleveXel Pharma has been granted a license by the SATT Sud Est, a technology transfer…

BiotechnologyCleveXel PharmaFranceLicensingOncologyPatentsSATT Sud Est

Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

Baxter and Merrimack enter exclusive licensing agreement for MM-398 compound outside the USA

24-09-2014

Baxter International and oncology specialist Merrimack have launched a collaboration to develop and commercialize…

Baxter InternationalBiotechnologyLicensingMerrimackMM-398OncologyUSA

Servier and CTI Biopharma collaborate on Pixuvri

23-09-2014

Leading French independent drugmaker Servier and US biotech firm CTI BioPharma have entered into an exclusive…

BiotechnologyCTI BioPharmaLicensingOncologyPixuvriServier

Boehringer Ingelheim and CureVac link on lung cancer immunotherapy

Boehringer Ingelheim and CureVac link on lung cancer immunotherapy

21-09-2014

Family-owned German drug major Boehringer Ingelheim and German clinical-stage biotech company CureVac…

BiotechnologyBoehringer IngelheimCureVacCV9202GlobalLicensingOncology

Biotie receives final European milestone from Lundbeck on Selincro French launch

Biotie receives final European milestone from Lundbeck on Selincro French launch

19-09-2014

Danish CNS drug specialist Lundbeck has brought Selincro (nalmefene) on the market in France. Selincro,…

BiotechnologyBiotie TherapiesFinlandFranceLicensingLundbeckNeurologicalSelincro

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

Swedish Orphan Biovitrum adds new molecule to its hemophilia collaboration with Biogen Idec

19-09-2014

Nordic biotech firm Swedish Orphan Biovitrum has added the preclinical fusion molecule rFVIIIFc-XTEN-vWF…

Biogen IdecBiotechnologyHematologyLicensingSobiSweden

Merck unit inks antibody drug conjugates deal with Sutro Biopharma

Merck unit inks antibody drug conjugates deal with Sutro Biopharma

18-09-2014

EMD Serono, a US subsidiary of Germany’s Merck KGaA has entered into a collaboration and license agreement…

BiotechnologyEMD SeronoLicensingMerck KGaAOncologyResearchUSA

Denovo Biopharma acquires Lilly’s enzastaurin for development as a personalized medicine

Denovo Biopharma acquires Lilly’s enzastaurin for development as a personalized medicine

17-09-2014

Privately-held San Diego, USA-based biotech firm Denovo Biopharma has acquired enzastaurin, a late-stage…

BiotechnologyDenovo BiopharmaEli LillyenzastaurinGlobalLicensingOncology

Merck Serono to partner with Lupin for emerging market exposure

Merck Serono to partner with Lupin for emerging market exposure

17-09-2014

Merck Serono, the biotech unit of Germany’s Merck KGaA, has entered a strategic partnership with Indian…

Antibiotics and Infectious diseasesBiotechnologyCardio-vascularDiabetesGermanyIndiaLicensingLupinMerck KGaAMerck Serono

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

UK cancer charity partners with Asterias Biotherapies on lung cancer vaccine

15-09-2014

The charity Cancer Research UK and its commercialization arm Cancer Research Technology (CRT), have reached…

Asterias BiotherapeuticsBiotechnologyBioTimeCancer Research TechnologyLicensingOncologyResearchUKVaccines

NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018

12-09-2014

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

Seattle Genetics and Genmab sign new antibody-drug conjugate deal

10-09-2014

Biotech companies Seattle Genetics of the USA and Denmark’s Genmab have entered into an additional…

BiotechnologyGenmabHuMax-TACLicensingOncologyResearchSeattle Genetics

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

Bristol-Myers returns rights to clazakizumab to Alder BioPharma

03-09-2014

USA-based drug developer Alder BioPharmaceuticals says it has regained the worldwide rights to clazakizumab,…

Alder BiopharmaceuticalsAnti-Arthritics/RheumaticsBiotechnologyBristol-Myers SquibbclazakizumabGlobalInflammatory diseasesLicensing

1 to 25 of 391 results

Back to top